Exiqon Buying Oncotech

Exiqon AS, a listed Danish provider of high-value gene expression analysis products, has agreed to acquire Oncotech, a Tustin, Calif.-based maker of extreme drug resistance diagnostic tests for cancer. The deal is valued at approximately $45 million in Exigon stock.


Oncotech has raised just under $15 million in total VC funding from firms like Southern California Ventures, U.S. Venture Partners, North Star Ventures, GC&H Partners and MedVenture Associates. www.exiqon.com www.oncotech.com